Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 6.93$. Average daily volumn in 3 months 1.47M. Market cap 6.92B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 8.47$. Total volume : 835.29k. Market state PRE
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
8.47$
Change
0.06
Volume
835.29k

Previous Close8.41
Open8.72
Day Range8.40-8.86
Bid8.27 x 1k
Ask8.31 x 1.3k
Volume835.29k
Average Volume1.47M
Market Cap6.92B
Beta0.44
52 Week Range5.71-13.34
Trailing P/E77.00
Foward P/E16.61
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).


Loading ...



Organization

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumย–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoringย–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
6.92B
Revenue:
4.93B
Total Assets:
19.23B
Total Cash:
655.49M


News about "Grifols, S.A."

GRLS.MC - Grifols SA | Stock Price & Latest News | Reuters

Source from : Reuters - 8 days ago

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes ...See details»


Grifols S.A. ADR

Source from : Wall Street Journal - 6 days ago

1 Day GIKLY 5.20% DJIA 2.18% S&P 500 3.09% Health Care/Life Sciences -0.45% Raimon Grifols Roura Joint Chief Executive Officer & Executive Director Grifols Escrow Issuer SA, Grifols SA, Grifols ...See details»


GRFS.O - Grifols SA - ADR | Stock Price & Latest News | Reuters

Source from : Reuters - 2 years ago

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes ...See details»


Grifols, S.A. (GIFOF)

Source from : Yahoo Finance - 3 years ago

The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a [โ€ฆ] Grifols appointed an executive chairman on Monday, as the Spanish ...See details»


Grifols SA - ADR - Level III

Source from : U.S. News & World Report - 7 days ago

Financial advisors can help clients navigate an inheritance by following these best practices.See details»


Client Profile: Grifols SA

Source from : OpenSecrets.org - 10 month ago

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple ...See details»


Grifols receives FDA clearance for AlphaIDโ„ข At Home, the first free service for U.S. consumers to determine their risk for alpha-1

Source from : Benzinga.com - 1 month ago

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»


Grifols SA PRF UNDATED EUR 0.05

Source from : Morningstar%2c Inc. - 11 days ago

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do ...See details»


Grifols S.A. reports Q3 results

Source from : Seeking Alpha - 26 days ago

To ensure this doesnโ€™t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»


Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS)

Source from : The Globe and Mail - 5 month ago

Kepler Capital analyst Dariusz Ubik maintained a Hold rating on Grifols SA (GRFS โ€“ Research Report) on July 1 and set a price target of EUR22.90. The companys shares closed last Friday at $12.49.See details»


GRFS Grifols, S.A.

Source from : Seeking Alpha - 13 days ago

To ensure this doesnโ€™t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»


Spanish pharmaceuticals firm Grifols reports 30% drop in nine-month profit

Source from : Euronews - 27 days ago

MADRID โ€“ Spanish pharmaceutical company Grifols reported a 30% drop in nine-month net profit on Tuesday, due in part to acquisition costs. Grifols said it was still on track to meet its full ...See details»


Grifols opens new medical protein purification plant in Dublin

Source from : The Irish Times - 1 month ago

Spanish pharma group Grifols has opened a large new extension at its Dublin site. The new albumin purification plant marks a significant upgrade for the Irish operation, which started life as a ...See details»


Grifols receives FDA clearance for AlphaID(TM) At Home, the first free service for U.S. consumers to determine their risk for alpha-1

Source from : MarketWatch - 1 month ago

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»